Name: Latest research reports of Ajanta Pharma Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Ajanta Pharma Ltd.

NSE: AJANTPHARM | BSE: 532331 | ISIN: INE031B01049 | Industry: Pharmaceuticals
| Mid-range Performer

2614.1000 13.40 (0.52%)

NSE Sep 05, 2025 15:31 PM

Volume: 103.0K

Ajanta Pharma Ltd.

11 May 2022

2614.10

0.52%

Ajanta Pharma (BUY): Margin stress continues

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Q4 revenue 6% ahead of our estimate but margins disappointed with gross/EBITDA margin contraction of 530bps/1050bps YoY to ~72%/24%

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr